Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Publication
Article
Pharmacy Times
Volume00
MYLAN BARRED FROM SELLING GENERIC TOPAMAX
A federal judge in NewJersey issued an injunctionpermanently barringMylan Pharmaceuticalsfrom selling generic topiramatetablets and capsulesin the United Statesbefore September 26,2008, the expiration dateof the patent for TOPAMAX(topiramate) heldby Ortho-McNeil NeurologicsInc. Mylan hadchallenged the validity ofthat patent and filed anabbreviated new drugapplication to market ageneric version of theepilepsy drug. The brandedmanufacturer counteredwith a patentinfringement complaintagainst Mylan and obtaineda preliminary injunctionagainst the genericfirm last fall.
Articles in this issue
can you READ these Rxs?
compounding HOTLINE
Pseudoephedrine Logs Need Constant Tending
Another Federal Court Rejects a Drug Importation Plan
Home Infusion Therapy Gets Patients Out of the Hospital
RESPy AWARD: Teamwork Is the Thread That Binds
Child-resistant Does Not Mean Childproof
ccpa SPEAKS OUT: CCPA Works to Improve Medicare Part D
Genetic Testing: Remarkable Resource or Invasion of Privacy?
case STUDIES
Risperidone May Treat Autism Behaviors
Actemra Achieves Its Goals for Treating RA
Potential Drug Interactions in Smokers and Quitters
Selenium May Help Men Reduce Cancer Risk
Successful Nexavar Phase 3 Trial Ends Early
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Content
